Adrulipase alfa

艾佐脂酶α

Report date: 2026/04/08 20:02:35

Base Information

Drug NameAdrulipase alfa
Drug Alias Name重组脂肪酶 - Mayoly-Spindler/AzurRx BioPharmaLipaseMS1819 recombinant lipaseMS-1819MS1819-SD +[6] 
ClassificationBiologics > Protein drugs > Enzyme > Recombinant enzymeBiologics > Protein drugs > Recombinant protein > Recombinant enzyme
Mechanisms of ActionTriglyceride modulatorsLipase replacements
TargetsTriglyceride
Therapy Area/IndicationsPancreatitis, ChronicExocrine Pancreatic InsufficiencyCystic Fibrosis +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesPolandTurkey +[7] 
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesMayoly-Spindler
China Registration ClassN/A

Develop Information

Active CompaniesAzurrx SasEntero Therapeutics Inc
Inactive CompaniesN/A
Active IndicationsExocrine Pancreatic InsufficiencyCystic FibrosisGastrointestinal Diseases
Inactive IndicationsPancreatitis, Chronic

Other Information

ATC CodeN/A
Related LinksN/A